In her current position, Dr. Albanese is involved with the development and implementation of patient care education and research, which focuses on diabetes and medication management in a Patient Centered Medical Home (PCMH) Physician Group practice. Currently she is the Program Director for the UB-Buffalo Medical Group PGY2 Ambulatory Care Residency Program. In 2009 Dr. Albanese became a Certified Diabetes Educator and in 2011 she became a Board Certified Ambulatory Care Pharmacist. Her curricular responsibilities include endocrinology, in addition to pharmaceutical care and self-care. In 2013 she was appointed the Chair of the Curriculum Committee for UB SPPS. She is an active member of the profession and an accomplished lecturer speaking on topics such as diabetes, obesity, and immunizations among others. She is also well published in peer reviewed journals, textbooks, and case-books.
Research interests are focused to the application of molecular imaging techniques such as positron emission tomography (PET) to assessing drug effects, including the study of migraine headache where we have looked at treatment as well as induction of headache. We have also had recent work looking at opiate receptors in the human brain using 11C-carfentanil, a radiopharmaceutical that binds to the mu opiate receptor.
The characteristics of positron emitting radio nuclides often make them ideal tracers for measuring drug effects. This includes the labeling drugs with PET radio nuclides such as C-11, or F-18. These nuclides allow for creation of labeled drugs nearly identical to their unlabelled counterparts. We have also used ³workhorse¹ radiopharmaceuticals such as FDG in a variety of settings ranging from measuring the uptake of glucose into white blood cells, to oral administration of this radiopharmaceutical, to application in the assessment of response to drugs in dementia. Other research areas include migraine headache, and neuroreceptor binding studies.
Dr. Brody is the Director of Experiential Education and Clinical Assistant Professor with the Department of Pharmacy Practice at the State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences. He specializes in clinical ambulatory care pharmacy practice with an emphasis in medication therapy management (APhA certified manager and trainer), immunization training / administration (APhA certified immunizer and trainer), and diabetes management (NISPC Certified Disease Manager from June 2005 - December 2008). He is also a PGY1 Community Pharmacy Residency Director and Clinical Consultant for Mobile Pharmacy Solutions (formerly VascuScript Pharmacy). As an educator, Dr. Brody lectured in several courses throughout the first three professional years of UB's PharmD curriculum and was the section coordinator of dermatology in the disease and pharmacotherapeutics course from 2005-2008, as well as the course coordinator of the first of six sequential pharmaceutical care courses from 2004-2008. He has created and developed the school's first formal Introductory Pharmacy Practice Experience (IPPE) program and currently serves as the course coordinator for all three levels of the IPPE curriculum (six courses) as well as maintain and co-coordinate the Advanced Pharmacy Practice Experience (APPE) program. He has also precepted numerous APPE and IPPE students and serves on a multitude of committees within the school. Dr. Brody is a member of several professional organizations which include AACP, APhA, ASHP, NYS-ACCP, PAWNY, PSSNY, Phi Lambda Sigma, and has served on several local, regional, and international committees of Kappa Psi Pharmaceutical Fraternity, Inc. After finishing his pre-pharmacy requirements at Canisius College, Dr. Brody attended the University at Buffalo and completed a dual major, receiving both a Bachelor of Science Degree in Biochemical Pharmacology in 2001 and then a Doctor of Pharmacy Degree in 2002. He pursued post-graduate clinical training and completed an IACP ambulatory care residency with both the University at Buffalo and Tops Pharmacy. In 2003, he accepted a shared faculty position as a Clinical Assistant Professor with the University at Buffalo School of Pharmacy and Pharmaceutical Sciences (UBSPPS) and as a clinical pharmacist managing Eckerd Pharmacy's PatientCARE Network in Western New York, expanding innovative community pharmacy practice at his site until 2007. Dr. Brody currently devotes the majority of his time to pharmacy academia, researching related educational outcomes, and the continuous development of UBSPPS' experiential education program. He has also established an ASHP/APhA Accredited PGY1 Community Pharmacy Residency Program with Mobile Pharmacy Solutions (formerly VascuScript Pharmacy), serving as the program director.
Director of the Pharmacotherapy Information Center
Primary research interests are in the fields of drug information and pharmacy informatics. Currently, Dr. Catanzaro is continuing to work in collaboration with other UB SoPPS faculty on projects with the NY State Department of Health (DOH). The projects involve post-marketing drug utilization literature evaluation as well as retrospective drug utilization review (DUR) research for the Office of Medicaid Clinical Drug Review Program. Additional projects for this year will involve the development and tracking of outcomes for the DOH Prescriber Education Program (PEP) as well as the development of a web-based Rapid Response Center for providing drug information in support of the PEP within the Pharmacotherapy Information Center.
Students interested in this type of research will have the opportunity to develop their literature retrieval and evaluation skills and professional writing skills. The DUR research component will provide the opportunity to learn how to analyze insurance claims databases to identify prescribing patterns and opportunities for optimizing appropriate medication use. Participation in the project may also lead to the opportunity for the student to become a published author.
With a supportive yet challenging style and a passion for people empowerment, Dr. Ceacareanu leads her research group to elucidate the cancer-preventive pharmacodynamics of insulin sensitizers - pharmacotherapies such as metformin, statins and omega-3 fatty acids. The goal of the Oncology Translational Research Lab is to develop a biomarker-driven surveillance and intervention protocol for glucose and cholesterol management in individuals with type 2 diabetes who are at risk for developing cancer.
Christopher J. Daly is a Clinical Assistant Professor at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Dr. Daly received his dual degree in doctor of pharmacy and master of business administration degree at the University at Buffalo. He went on to complete a PGY-1 Community Pharmacy residency with UNC Eshelman School of Pharmacy and Moose Pharmacies. Dr. Daly’s faculty charge is to lead the innovation of new practice opportunities for advanced clinical outpatient pharmacy. His work seeks to establish a Community Pharmacy Practice Based Research Network developing various pharmacy models in the Western New York region. This is integrated into his educational and research responsibilities. His academic and research passions are innovative community pharmacy models, entrepreneurialism, social and administrative pharmacy practice sciences, and clinical based outcomes research. Dr. Daly has been an active advocate for community pharmacy for over 10 years. He is currently a third generation pharmacist.
My goal as a pharmacist is to help improve the health outcomes (both physical and mental) of all individuals through education, counselling and evidence-based interventions. My personal goal is to serve and volunteer for under-served populations whenever I can.
Research interests in pharmacoeconomics, outcomes research, and health services research. Specific areas of research include cost-effectiveness clinical pharmacy services.
Main interests areas: 1. Research and application of the laws, rules and regulations, both federal and state affecting pharmacy practice issues in NYS. These include current legislative issues affecting the expansion of pharmacist‘s responsibility in patient care along with the application of business models for improving the corresponding revenue streams that any legal changes may create. 2. Studying areas to improve the recognition, and reporting of medication errors and systems for improvement of practice sites for enhancement of patient outcomes. 3. Business plan modeling for pharmacy related businesses to improve efficiency and profitability.
Dr. Nicholas M. Fusco is employed as Clinical Assistant Professor, Department of Pharmacy Practice at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences (UB-SPPS), since 2013. He earned his PharmD from UB-SPPS (2010) and completed his PGY1 Pharmacy Practice and PGY2 Pediatric Specialty residencies at the University of Maryland School of Pharmacy (2010-2012). He received his Board Certification in Pharmacotherapy (BCPS) in 2011 and his Board Certification in Pediatric Pharmacy Practice (BCPPS) in 2016. Dr. Fusco practices and teaches in acute care general pediatrics. His research interests include infectious diseases, cystic fibrosis and inter-professional education (IPE).
Research conducted at the Neurologic Institute focused to neuropharmacology and a clinical research interest in PK-PD of neuroactive compounds. 1. Ethanol Pharmacology: Conducts clinical studies to examine the pharmacokinetic and pharmacodynamic models of ethanol pharmacologic effects. 2. Headache: Clinical management models for headache pharmacotherapy. 3. Alzheimer‘s: Clinical management models for Alzheimer‘s pharmacotherapy.
Dr. Krajewski joined the faculty in 2012 after completing a PGY1 residency at the Buffalo Veteran Affairs Medical Center. He is a 2011 University at Buffalo graduate. His primary focus is retrospective drug utilization review (RetroDUR) as a part of the collaboration with the New York State Department of Health. He also has a faculty appointment within the University at Buffalo School of Dental Medicine where he has regular clinic hours performing medication reconciliation for patients of the dental clinic. His research interests focus on drug utilization, underserved populations, and transitions of care best practices.
Dr. Jeffrey Lombardo is Associate Director for UB’s patient safety organization Empire State Patient Safety Assurance Network. In this role he facilitates organization participation, logistics and implementation with participating sites as well as reviewing data and presenting reports on findings. Working with Medical Oncologists he is tracking patient outcomes and advising physicians on best practices for cancer patients making full use of his specialty pharmacy certification in oncology. Dr. Lombardo is also a member of the SUNY Global Health Institute where he will be bringing his patient safety and oncology expertise to partner schools like the University of the West Indies for various collaborations.In Jamaica he will be partnering with UWI on studies on medical marijuana and pursuing new initiatives for the University at Buffalo’s medication management research network. (MMRN) Additionally Dr. Lombardo is a member of UB‘s Center for Integrated Global Biomedical Sciences. Dr. Lombardo received his Doctorate in Pharmacy from the University at Buffalo where he currently holds a Research Assistant Professor Title. He has completed research and co-authored several articles on topics involving chemotherapy in the field of solid tumors. Dr. Lombardo has worked in various cancer pharmacies throughout Western New York as well a national oncology specialty pharmacy. These roles provided Dr. Lombardo with expertise in contracting with managed care plans and companies in the pharmaceutical industry. In addition to these accomplishments Dr. Lombardo has exhibited and presented his work at the American Society of Clinical Oncology, American Society of Health System Pharmacists and Value Based Cancer Care Symposiums.”
Research interests areas: 1. Pharmacogenomics of antiretrovirals in patients with HIV-associated neurocognitive disorders 2. Mechanisms of drug-drug interactions in patients with HIV infection 3. Incorporating pharmacokinetics, pharmacodynamics and pharmacogenomics in studying the effects of antiretrovirals on the central nervous system
Gene D. Morse, Pharm.D., FCCP, BCPS, is a tenured, SUNY Distinguished Professor in the School of Pharmacy and Pharmaceutical Sciences and Director of the UB Center for Integrated Global Biomedical Sciences. He is also the Co-Director of the SUNY Global Health Institute. Dr. Morse has been actively involved in drug development research since the introduction of antiretrovirals for HIV in 1986, with more recent emphasis on HCV infection and drug development. He has National Institute of Allergy and Infectious Diseases support for the UB AIDS Clinical Trials Group, Pharmacology Specialty Laboratory and a contract for the HIV Clinical Pharmacology Quality Assurance Program. These programs integrate with the NIH Fogarty International Center AIDS International Training and Research Program, which Dr. Morse directs with the University of Zimbabwe and is home to the Center of Excellence in Clinical Pharmacology. Dr. Morse also directs the UB HIV Clinical Pharmacology Laboratory, which has gained an international reputation for its work in bioanalysis, pharmacokinetics, and pharmacogenomics. In addition, Dr. Morse is director of the Empire State Patient Safety Assurance Network, a federally certified patient safety organization and a network for health information technology innovation. Dr. Morse is the director of the UB Translational Pharmacology Research Core. He is also associate director for the Clinical Trials Methods and Technologies Pillar for the Clinical and Translational Sciences Institute at the University of Rochester Medical Center. Dr. Morse is co-founder of the Buffalo Jamaica Innovation Enterprise, a partnership between UB the University of the West Indies and the Jamaica Ministry of Health. This project has established the Jamaica Center for Infectious Diseases Research. Dr. Morse has more than 25 years of NIH, industry and philanthropic research support with extensive experience in grant applications and mentoring. Dr. Morse received the 2012 Volwiler Research Achievement Award from the American Association of Colleges of Pharmacy.
Fellowship Director, Pharmacoeconomics. Research interest areas: 1. Pharmacoeconomic evaluation of antimicrobial therapy for pneumonia and geriatric therapy. 2. Clinical trails of developmental antibacterial agents.
Scholarly interests are in the area of global health, underserved patient care, and education. Dr. Prescott is passionate about teaching students in the area of global health and underserved patient care. She works with interprofessional teams in low-middle income countries (Dominican Republic) and organizes various student involvement in global health activities. In regards to underserved care, Dr. Prescott assists with coordinating student involvement and optimizing pharmaceutical patient care at local free clinics.
Teaching foci: - Pediatric Pharmacy - Patient Assessment - Pharmacy Leadership Scholarship foci: - Clinical: Pediatric pulmonary disease (cystic fibrosis); pediatric infectious diseases; and, immunization. - Pharmacy Education: Pharmacy curricula; and, active learning approaches.
Research interests include design of new and innovative drug delivery systems. Current projects include the development of an automated (robotic) filling, metering and dispensing system for transdermal gels.
Practice specialty is the academic side pharmaceutical compounding and institutional dispensing, mentoring students who have career goal interests in academia. These students research, prepare and present lecture materials to the P2-4 classes in Professional Practice (PHM 651/652 LAB/LEC) and Advanced Pharmaceutical Compounding Elective (PHM 540).
Licensed pharmacist for over twenty years providing clinical and strategic planning to a broad spectrum of health care providers. Concentrated background in formulary review process, evidence-based medicine, pharmacoeconomic and disease state evaluations (DUE). Accomplished in planning, organizing, coordinating, and evaluating patient care programs in diverse segments of health care market. Highly knowledgeable about management of pharmacy benefits, contracting, drug utilization and analysis and formulary design.
Clinical Practice Site: Lifetime Health Medical Group, MedSense Clinical Pharmacy Program Therapeutic Areas of Interest: -Ambulatory Care (Diabetes, Hypertension, Hyperlipidemia, Cardiovascular Disease, Osteoporosis, Asthma/COPD) -Clinical Pharmacy Services and Medication Therapy Management -Self Care Research interest areas include: 1. Patient-centered pharmacotherapy management of ambulatory disease states 2. Effect of pharmacist intervention on health care and economic outcomes 3. Ambulatory management of type 2 diabetes 4. Lipid and blood pressure management in the ambulatory type 2 diabetes population
Research works focuses in the area of Clinical Pharmacokinetic and Pharmacodynamic Research of Immunosuppressive Regimens in Renal Transplantation. This clinical research program has been an ongoing collaborative program with the Division of Nephrology at Erie County Medical Center for over 15 years focusing on the pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressive agents during renal transplantation:
Current and upcoming clinical research endeavors focus upon pharmacokinetics of immunosuppressive drugs in relationship to pharmacodynamics of immunologic markers and targeted pharmacogenomic endpoints in relation to race and gender of the renal transplant recipient. Research projects may provide the student with exposure to a variety of biomedical technologies including LCMSMS, flow cytometry and Q-PCR. These projects provide Pharm.D. students with an opportunity to explore clinical and translational research projects though a clinical research team (i.e. Pharm.D.s, physicians, nurse clinicians, immunologists, geneticists, biostatisticians, etc.) by participation in clinical pharmacology sub-studies in renal transplant patients with the endpoint to provide safe and efficacious immuosuppression (e.g. cyclosporine, prednisone, mycophenolic acid) among different patient groups.
In addition, this funded clinical research program has focused on the pharmacokinetics and dynamics of glucocorticoids with specific emphasis on the impact of the factors of gender, race, acute rejection, time post-transplant, immunologic response and chronic adverse effects in the renal transplant population. This research program has also evaluated the pharmacodynamics of anti-lymphocyte induction agents as well as glucocorticoid pharmacokinetics during various "steroid withdrawal" protocols during a multi-center clinical trial.
I am Clinical and Translational Pharm.D. Scientist and PI of R01AI111990 which seeks to investigate the Pharmacokinetics and Pharmacodynamics of Polymyxin Combinations. This R01 is interdisciplinary and blends diverse areas including microbiology and antimicrobial pharmacology with next generation sequencing and a number of infection models with an outstanding team of Pharm.D., M.D., and Ph.D. Co-Investigators. I am an internationally leading expert on antimicrobial pharmacology. In my early work in at Wayne State University, I completed new studies to optimize vancomycin dosing to combat heterogeneous resistance in Staphylococcus aureus by using PK/PD approaches to evaluate novel dosage regimens and antibiotic combinations. With the recent spread of multidrug-resistant Gram-negative bacteria, at the University at Buffalo, I developed an independent, federally funded research program, and expanded my research to refine exposure response approaches in a number of agents including colistin, polymyxin B, beta-lactams, and new combinations involving beta-lactam inhibitors against these very problematic pathogens. From 2008 to 2012, I have been a Co-investigator and PI of a subcontract at the University at Buffalo for R01A1079330 (PI Nation), a $2.3 million award from NIH. I am currently Principal Investigator of R01AI111990 a $4.4M grant which seeks to investigate the Pharmacokinetics and Pharmacodynamics of Polymyxin Combinations.
Research interests focus on identifying and reducing medication related fall risk in the elderly. Using the Medication Therapy Management (MTM) model, he is developing clinical decision support tools to access medication falls risk, medication cognition impairment and inappropriate medications in the elderly.